Orthofix Medical Inc. (NASDAQ:OFIX) Given Average Rating of “Hold” by Analysts

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.00.

Several analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a report on Thursday, January 22nd. Stifel Nicolaus began coverage on Orthofix Medical in a research note on Tuesday, October 28th. They issued a “buy” rating and a $22.00 target price for the company. Barrington Research upped their price target on Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Finally, TD Cowen started coverage on Orthofix Medical in a report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 price objective for the company.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, CEO Massimo Calafiore sold 9,797 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $15.21, for a total transaction of $149,012.37. Following the completion of the sale, the chief executive officer directly owned 217,237 shares in the company, valued at approximately $3,304,174.77. This trade represents a 4.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Julie Andrews sold 4,873 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total transaction of $70,073.74. Following the sale, the chief financial officer owned 58,039 shares in the company, valued at approximately $834,600.82. The trade was a 7.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 24,270 shares of company stock worth $370,958 in the last 90 days. 1.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Orthofix Medical

Several hedge funds and other institutional investors have recently bought and sold shares of OFIX. CWM LLC lifted its holdings in Orthofix Medical by 99.0% in the third quarter. CWM LLC now owns 1,920 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 955 shares during the period. State of Alaska Department of Revenue bought a new position in shares of Orthofix Medical in the 3rd quarter worth approximately $30,000. Strs Ohio purchased a new position in shares of Orthofix Medical in the first quarter worth approximately $150,000. Mackenzie Financial Corp bought a new stake in Orthofix Medical during the third quarter valued at approximately $148,000. Finally, Diversified Trust Co. purchased a new stake in Orthofix Medical during the fourth quarter valued at approximately $159,000. Institutional investors own 89.76% of the company’s stock.

Orthofix Medical Trading Up 0.8%

Shares of OFIX stock opened at $12.80 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.47 and a quick ratio of 1.38. The business has a 50-day moving average of $14.77 and a 200 day moving average of $14.54. The stock has a market capitalization of $506.88 million, a PE ratio of -4.22 and a beta of 0.78. Orthofix Medical has a 1-year low of $10.24 and a 1-year high of $20.48.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.